Neurodegenerative diseases: The potential of cyclophilin inhibition

In a new article in Drug Target Review, Dr. Hans Fliri highlights the potential of cyclophilin inhibition to combat neurodegenerative diseases.

Neurodegenerative diseases are defined as hereditary and sporadic conditions characterised by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral structures of the nervous system, affecting movement (ataxias) or mental functioning (dementias) and include diseases such as Alzheimer’s (AD) and Parkinson’s Disease (PD), other dementias, degenerative nerve diseases, glaucoma, stroke, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Huntington’s disease, muscular dystrophies, and others. Dementias are the greatest disease burden, with Alzheimer’s disease contributing approx. 60-70% of cases.

Read more.